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Genetic Markers and Danger Signals in
Stevens-Johnson Syndrome and Toxic
Epidermal Necrolysis
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ABSTRACT
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening adverse reactions,
which could be induced by a variety of drugs. It was proposed that human leukocyte antigen (HLA)-restricted
presentation of antigens (drugs or their metabolites) to T lymphocytes initiates the immune reactions of SJS
TEN. However, the genetic susceptibility and the exact pathogenesis were not clear until the recent studies.
We first identified that HLA-B*1502 is strongly associated with carbamazepine (CBZ)-induced SJSTEN and
HLA-B*5801 with allopurinol-SJSTEN in Han Chinese. The same associations had been validated across dif-
ferent human populations. For the downstream danger signals, Fas-Fas ligand (FasL) and perforingranzyme
B had been advocated as cytotoxic mediators for keratinocyte death in SJSTEN. However, expression levels
of these cytotoxic proteins from the skin lesions were too low to explain the distinct and extensive epidermal ne-
crosis. Our recent study identified that the granulysin, a cytotoxic protein released from cytotoxic T cells or
natural killer (NK) cells, is a key mediator for disseminated keratinocyte death in SJSTEN. This article aims to
provide an overview of both of the genomic and immunologic perspectives of SJSTEN. These studies give us
a better understanding of the immune mechanisms, biomarkers for disease prevention and early diagnosis, as
well as providing the therapeutic targets for the treatments of SJSTEN.
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INTRODUCTION
Drug hypersensitivity is a major clinical problem.
Among the many types of drug hypersensitivity, SJS
and TEN are the most serious and life-threatening ad-
verse reactions. According to the clinical presentation
and immunohistochemistry data, SJS and TEN have
been considered as an immune disorder, involving
both the adaptive and innate immune reactions. Ap-
plying techniques of pharmacogenomics and molecu-
lar biology in recent studies further revealed that the
genetic disposition as well as immune mediators are
important for the development of SJS and TEN. Al-
though Fas-FasL interaction was previously consid-
ered to be the main effector in triggering apoptosis of
keratinocytes, recent evidence suggested that
granulysin, a cytotoxic protein produced by cytotoxic
T lymphocytes (CTLs) and NK cells, is the one actu-
ally “turns on” the extensive apoptosis in keratino-
cytes.1 In this article, we review the genomic and im-
munologic perspectives of SJSTEN.
CLINICAL MANIFESTATIONS OF SJSTEN
SJSTEN are life-threatening severe cutaneous ad-
verse reactions, presenting 10-40% mortality rate. SJS
and TEN are classified as the same disease with dif-
ferent spectrums of severity according to the magni-
tude of epidermal detachment.2 Early symptoms of
the abrupt onset of SJS usually start with fever, sore
throat, and malaise, following by rapidly developing
blistering exanthema of macules and target-like le-
sions accompanied mucosal involvement with less
than 10% of skin detachment.2 TEN has similar clini-
cal presentations with a more extensive separation of
large sheets of epidermis from the dermis (greater
than 30%) and a higher mortality rate (30-40%).3 The
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skin lesions usually begin on the trunk and spreads
proximally in both of the SJS and TEN patients.2,3
Although having a low incidence, complications
and its sequelae of SJSTEN can results in death or
disability in previously healthy people.4 Patients expe-
riencing SJSTEN are affected irreversible mucosal
damage and the most serious ocular sequelae.
Synechiae, corneal ulcers, symblepharon, and
xerophthalmia are frequent ocular complications dur-
ing the progression of SJSTEN,5 and photophobia
and xerophthalmia are commonly developed eye se-
quelae affected SJSTEN survivals lifelong.6 Other in-
ternal organ involvements at mucosal surfaces are
also common in SJSTEN. With the increasing sever-
ity, abnormalities in respiratory tract,7 gastrointesti-
nal tract,8 liver, andor kidney are occasionally re-
ported.9
The histopathology findings show that the signifi-
cant feature of large portion epidermis separation
from dermis is induced by massive keratinocyte
apoptosis in SJS and TEN.10 Although Fas-FasL inter-
action was previously considered to be the main ef-
fector in triggering apoptosis of keratinocytes, evi-
dence suggests that the granulysin1 is the one actu-
ally “turns on” apoptosis of keratinocyte.11 The main
purpose of this review is to elucidate the pathomecha-
nism of SJS and TEN in genetic and immunologic
point of views.
GENETIC MARKERS RELATED TO SJSTEN
Genetic association between HLA alleles and SJS
TEN was found from several reports, and the ethnic-
ity specific feature is emphasized these years. A sig-
nificantly strong correlation was first found in Han
Chinese in 2004.12 CBZ-induced SJSTEN patients
carried 100% of HLA-B*1502 allele, and only 3% HLA-
B*1502 carriers tolerated CBZ.12 According to its ab-
sence in Caucasians13 and Japanese,14 HLA-B*1502 al-
lele seems uniquely limited in Han Chinese ancestral
Asians and might be an explanation for the extremely
high risk of CBZ-induced SJSTEN in Southeast
Asians comparing to Caucasians and Japanese. Later
studies conducted in the South-East countries, includ-
ing Hong Kong, Malaysia, India, Singapore, Thailand,
Vietnam, Indonesia, and Philippines, were further
confirming its high prevalence (2.3% to 8.4%) of this
ethnic specific allele.15 Because of the ethnic spe-
cialty in HLA-B*1502, CBZ and some similar struc-
tural anticonvulsants were fully studied. One hundred
percent CBZ-induced SJS was HLA-B*1502 in Thai-
land people.16 Malay and Chinese carried 15.7% and
5.7% of HLA-B*1502, respectively, and had 75% inci-
dence of HLA-B*1502 in CBZ-SJS or TEN.17 A lower
prevalence (2.5%)18 and 75% incidence of HLA-B*1502
in CBZ-induced SJS were reported in Indians.19
Other than HLA-B*1502, HLA-B*5901 has been
suggested as a candidate marker in CBZ-induced SJS
in Japanese with 15.16 relative risk20; however, due to
its small sample size (10 patients), further investiga-
tion is needed to validate this finding. In addition,
HLA-A*0206, was proposed as a marker in SJSTEN
according to the ocular complications in Japanese.21
HLA-B*5801 allele is another genetic marker found
to have an association with a commonly prescribed
drug for decreasing uric acid level in hyperurice-
mia―allopurinol. In Taiwanese, it was 100% pre-
sented in patients with allopurinol-induced severe cu-
taneous adverse reactions, but only 15% in allopurinol
tolerant patients.22 The same strong association was
confirmed in a Thai population.23 However, findings
from Japanese population remain to clarify. A moder-
ate association (4 out of 10) in a Japanese popula-
tion14 was reported. Opposite to this finding, Kano et
al. suggested that HLA-B*4801 but not B*5801 was as-
sociated with CBZ-induced drug rash with eosino-
philia and systemic symptoms (DRESS).24 In addi-
tion, the ethnic limitation also presents in HLA-B*
5801 on its low allele frequency in Caucasians.25
Moreover, an antiretroviral drug, abacavir, can
cause drug hypersensitivity and was linked to HLA-B*
5701 allele. The combination of HLA-B*5701, HLA-
DR7, and HLA-DQ3 once reported having a 100% pre-
dictability of the abacavir-induced hypersensitivity.26
Further study demonstrated that the prevalence of
HLA-B*5701 was high in Caucasians and suggested
that prior screening of the carriage of HLA-B*5701
could effectively reduce the abacavir hypersensitiv-
ity.27 In contrast to the high prevalence of HLA-B*
5701 and incidence of abacavir hypersensitivity, none
of the patients with Asian ancestry in Korea carried
HLA-B*5701.28
DRUG-SPECIFIC, HLA-DEPENDENT, T-CELL-
MEDIATED IMMUNITY IN SJSTEN
The discoveries of the involvement of HLA-
dependent presentation of an offending drug or its
metabolites for T-cell activation29,30 demolished the
“hapten hypothesis”31 in severe drug hypersensitiv-
ity. The proposed pharmoco-immune (p-i) concept32
is the mainstream explanation for the drug-induced
delay cutaneous adverse reactions, suggesting the di-
rect and non-covalent binding between a drug and T-
cell receptors (TCR) with HLA molecules takes the
responsibility for the drug-induced immunity (Fig. 1).
The pathogenesis of the induction of cytotoxic re-
sponses in SJSTEN is generated by the recognition
of offending drugs to HLA class I molecule initiated
T-cell activation which results a clonal expansion of
CD8+ cytotoxic T-cells in skin.33 Our findings, the
strong associations between HLA-B*1502 and CBZ12
as well as the HLA-B*5801 and allopurinol,22 support
that drug-induced SJSTEN is a HLA-restricted im-
munity.12 Furthermore, our later results verified 5
peptides showing high affinities for HLA-B*1502, pro-
viding CBZ recognition of HLA, locating at antigen
presenting cells.34,35
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Fig. 1 A model of keratinocyte apoptosis induced by the immune 
synapse of drug-HLA-TCR interaction in SJS/TEN. As ilustrated, the 
immune response may be triggered by the binding of an antigenic 
drug (e.g. carbamazepine [CBZ]), to a specific HLA alele (e.g. HLA-
B*1502) on a keratinocyte, which are the main antigen presenting 
cels (APC) in SJS/TEN. Then, specific T cel receptors (TCR) of the 
CD8+ cytotoxic T lymphocytes (CTLs) recognize the drug-HLA 
complex. Upon the activation, CTLs or NKT cels produce cytokines 
and chemokines, as wel as the cytotoxic proteins, particularly, secre-
tory granulysin and lead to extensive keratinocyte apoptosis.
INVOLVEMENT OF NATURAL KILLER CELLS
IN SJSTEN
In addition to CTLs, NK cells also involves in SJS
TEN. The blister cells in skin lesions of SJSTEN-
affected patients were mainly CTLs and NK cells36;
moreover, HLA class I-binding proteins have activat-
ing (KAR, killer activating receptor) or inhibitory
(KIR, killer inhibitory receptor) cytolytic functions for
regulating NK cells.37 Nassif A. et al.29 further dem-
onstrated an observation of the infiltration of CTLs
and NK cells in skin lesions in TEN patients. Our re-
cent study also demonstrated that granulysin, se-
creted from CTLs and NK cells, is a key effector re-
sponsible for keratinocytes death in SJSTEN.1
DANGER SIGNALS INDUCING EXTENSIVE
KERATINOCYTE APOPTOSIS IN SJSTEN
Upon proposed immunopathogenesis of SJSTEN,
the general agreed central hypothesis is the T-cell-
mediated massive apoptosis in keratinocytes. Until
recently, there are three reported pathways advo-
cated as basic effectors: Fas-FasL interaction, perfo-
ringranzyme B, and the granulysin.
Fas-FasL-INDUCED APOPTOSIS
Although Fas-FasL-induced apoptosis in keratino-
cytes is one of the most thoroughly studied immune
mechanism in SJSTEN, inconsistent findings of Fas,
FasL, and soluble FasL (sFasL) questioned the origi-
nal hypothesis from Viard et al.11
Fas was discovered to cause cell death upon bind-
ing with its ligand in SJSTEN. Viard et al.11 sug-
gested the activated Fas servers as a death receptor
in triggering apoptosis of keratinocytes in SJSTEN.
The cytoplasmic death domain of Fas undergoes con-
formational changes upon recognition of FasL. The
Fas-FasL then recruits a Fas-associated death domain
protein (FADD) which has a affinity to bind to both of
the Fas death domain and procaspase 8. Once the
procaspase 8 is recruited by FADD, the multiple cop-
ies of procaspase 8 are brought together and autoacti-
vate themselves to caspase 8 which triggers the cas-
pase cascade for intracellular DNA degradation.38
One study concluded the same result as Viard et al.
by incubating cell-free supernatants of blister fluid
containing sFasL secreted from keratinocytes and not
resulting in apoptosis in keratinocytes.39
Viard et al. also showed that FasL presented on the
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cell surface of keratinocytes in TEN patients and
sFasL was found to have high levels in the serum, but
not in patients with maculopapular drug reaction or
normal persons.11 Metalloproteinases (MPs) present
at cell surface in many tissue types, including kerati-
nocytes40 and cleave FasL into sFasL at its TNF-
homologous portion.41,42 The high sFasL serum level
observed in TEN patients might cause by the MP
cleavage reaction. A study also consistently found an
apparent elevation of sFasL within 2 days after the on-
set of skin damage in a TEN patient.43 Testing the se-
rological sFasL for a short period at the beginning of
onset may help to define the progress of SJSTEN.
Controversial interpretations disagreed with either
the source of FasL or its role in apoptosis effector.
Studies demonstrated that FasL is not located at the
extracellular membrane surface of keratinocytes, but
rather transporting to the cell surface upon suffering
keratinocyte damage.40,44 Abe et al.45 found that the
apoptosis of cultured keratinocytes was induced by
adding high levels of sFasL containing sera isolated
from a SJSTEN patient, and was blocked by addition
of anti-FasL monoclonal antibody. They also showed
the peripheral blood mononuclear cells (PBMCs) of
TEN patients were the sites produced high levels of
sFasL.45
Since Amato et al.46 first reported the treatment of
intravenous immunoglobulins (IVIG) in a SJS patient,
many studies subsequently applied IVIG to treat the
SJS and TEN patients. IVIG therapy is a treatment
based on the hypothesis of Fas-FasL interaction, by
blocking FasL binding to the Fas receptor interferes
with the downstream signaling for triggering apopto-
sis of the keratinocytes.11 Although evidence seemed
to show the effectiveness of IVIG in in vitro stud-
ies,11,47 benefits were inconsistently seen in neither
the mortality nor the progression of skin detach-
ment,48-52 which yield the controversial role for the
IVIG treatment in SJSTEN.
PERFORINGRANZYME B APOPTIC PATH-
WAY
High concentrations of granzyme B was found in
TEN blister fluid.53 Nassif A. et al.54 presented a con-
tradictory hypothesis to the Fas-FasL interaction by
showing that the cytotoxicity from the blister fluid
mononuyclear cells in TEN could be blocked by in-
hibitors of perforingranyzyme B rather then blocked
by an anti-Fas monoclonal antibody. Perforin and
granzyme B are stored in secretory granules of acti-
vated CTLs and NK cells.55 Perforin binds and
punches a channel in the membrane of target cells
for entering of the granzyme B to activate the caspase
cascade and its following apoptotic pathways.56,57
OTHER CYTOKINES AND SIGNALS IN-
VOLVED IN THE PATHOGENESIS OF SJS
TEN
In addition to Fas-FasL or perforingranzyme B path-
ways, some cytokines, including tumor necrosis fac-
tor (TNF)-α, interferon (IFN)-γ,39 and interleukin
(IL)-10,39 were also found to be up-regulated in SJS
TEN. Blister cells of SJSTEN were reported to se-
cret IFN-γ and stimulate keratinocytes to express
TNF-α, FasL, and IL-10 which were present in higher
concentrations in the blister fluids as a defense
mechanism against CTLs.39 TNF-α has been reported
abundantly presenting in the keratinocytes of epider-
mis,58,59 blister fluid mononuclear cells and macro-
phages53,58,59 and PBMCs60 in SJSTEN. TNF-α has
been suggested having an up-regulating function in
Fas and FasL60 and via the activation of TNF-receptor
1 (TNF-R1), initiating the downstream FADD and
caspases.61,62 Apoptosis activation in TEN patients
had been implied to be induced by TNF.10 In addi-
tion, little evidence showed that TNF-α also can acti-
vate TNF-related apoptosis-inducing ligand (TRAIL)
and its receptors (TRAIL-Rs), which may result in the
activation of FADD apoptotic pathway.63 Interest-
ingly, contradictory to TNF-α apoptosis inducing role,
its binding to TNF-R1 can up-regulate NF-κB64 and
associate with an anti-apoptotic in keratinocytes.65
Anti-TNF therapy once was thought to be a possible
potential treatment for TEN patients; however, no
beneficial effect was concluded from anti-TNF by tha-
lidomide in TEN.66
There was one study that supported both of the
Fas-FasL and perforingranzyme B pathways in
keratinocytes apoptosis.53 This study found an in-
creasing pattern of TNF-α, perforin, granzyme B, and
FasL accompanied with the severity, ranging from
the mildest maculopapular rashes to the severest
TEN, and suggested that the perforingranzyme B
played as the major effectors and Fas-FasL interac-
tion was probably related to the severer adverse drug
reactions.
GRANULYSIN IS THE MAJOR FACTOR FOR
KERATINOCYTE APOPTOSIS IN SJSTEN
Recently, we found secretory granulysin servers as a
major cytotoxic molecule responsible for widespread
keratinocyte necrosis in SJSTEN,1 instead of those
previously reported sFasL, granzyme B, or perforin.
We performed global gene expression profiling of the
blister cells and found that granulysin RNA was the
most significant cytotoxic molecule expressed.
Granulysin protein concentrations in the SJSTEN
blister fluids were two to four orders of magnitude
higher than perforin, granzyme B or sFasL concen-
trations, and depleting granulysin reduced the cyto-
toxicity (Fig. 2). Westernblot analysis showed that
granulysin in the fluids was predominantly the 15-
Genetics and Signals in SJSTEN















Fig. 2 Pathogenesis of epidermal necrosis and disseminated keratinocyte apoptosis in SJS/TEN. Due to the 
signals of immune synapse, the CTLs and NK/NKT cels immigrate to the epidermis of skin. CTLs, and NK/NKT 
cels produce a large amount of immune mediators (e.g., soluble FasL [sFasL], perforin, grazyme B, and granu-
lysin) into the extracelular space. In particular, secretory granulysin, expressed at a very high level in the skin le-
sions, is a main weapon of CTLs, NK, and NKT cels, atacks keratinocytes and results in extensive epidermal 
necrosis and blister formation. By comparison, granzyme B/perforin and Fas/FasL are produced via granule exo-
cytosis upon cel-cel contact, and present in lower concentrations than granulysin in the inflammatory lesions. Af-
ter encountering the atacks of these cytotoxic proteins, keratinocytes are damaged and then the caspase 
signaling pathway turns on, leading to apoptosis progress. 
kDa secretory form. In vitro, purified 15-kDa
granulysin exhibited significant cytotoxicity at the
level presenting in the SJSTEN blister fluids. How-
ever, sFasL, perforin, and granzyme B concentrations
in the SJSTEN blister fluid had minimum cytotoxic-
ity. A further injection of granulysin into mouse skin
resulted in a SJS-TEN-alike skin necrosis.1 Thus, our
findings demonstrated that granulysin, not granzyme
B, perforin or sFasL as previously implicated, is the
key molecule responsible for the disseminated kerati-
nocyte death in SJSTEN. Following this line, Abe et
al.45 further reported that an increasing serum level
of granulysin could serve as an early diagnostic
biomarker for SJSTEN.
Granulysin is a cationic cytolytic protein produced
by CTLs, NK and NKT cells.67 The 15-kDa granulysin
was proposed as a precursor of the 9-kDa form.68,69 In
addition to having the cytotoxic effect, granulysin
also was demonstrated its chemoattractant ability for
T lymphocytes, monocytes and other inflammatory
cells, and activation function in the expression of a
number of cytokines, including RANTESCCL5,
MCP-1, MCP-3, MIP-1αCCL3, IL-10, IL-1, IL-6 and
IFN-α.70
However, much of SJSTEN remains in mystery.
How does taking a drug lead to secretion of
granulysin? How does CD8+TNK and NKT cells
regulate the secretion of granulysin in SJSTEN? The
specific relationship among offending drugs, HLA al-
leles, and cytotoxic signals from CLTsNKNKT
cells in SJSTEN remains further investigation.
CONCLUSION
Increasing data have revealed that the genetic predis-
position and immune mediators play important roles
in the drug hypersensitivity. As reviewed in this arti-
cle, it is known that HLA alleles associated with SJS
TEN may be variable among different human popula-
tion. These HLA alleles may be not only responsible
for the genetic susceptibility, but also play a patho-
genesis role, which may present the drugsmetabo-
lites to CTLs for the initiation of the downstream dan-
ger signals in the disease. In addition to Fas-FasL,
perforingranzyme B biomarkers, the secretory
15 kDa granulysin, is now known to be the major
weapon of CTLsNKNKT cells and leads to the ex-
Chung WH et al.
330 Allergology International Vol 59, No4, 2010 www.jsaweb.jp
tensive epidermal necrolysis in SJSTEN. Under-
standing the molecular mechanism of the interaction
of HLA, offending drugs and TCR, as well as CTLs
NK cells activation, would facilitate the development
of new approaches for the management of SJSTEN.
In conclusion, those transitional studies offer us a bet-
ter understanding of the immune mechanisms,
biomarkers for disease prevention and early diagno-
sis, as well as providing the therapeutic target for the
treatment of SJSTEN.
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